KR870010183A - 합성 펩티드를 함유하는 복합 면역원 - Google Patents
합성 펩티드를 함유하는 복합 면역원 Download PDFInfo
- Publication number
- KR870010183A KR870010183A KR870004111A KR870004111A KR870010183A KR 870010183 A KR870010183 A KR 870010183A KR 870004111 A KR870004111 A KR 870004111A KR 870004111 A KR870004111 A KR 870004111A KR 870010183 A KR870010183 A KR 870010183A
- Authority
- KR
- South Korea
- Prior art keywords
- complex
- synthetic peptide
- hepatitis
- coat protein
- virus coat
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 2
- 230000002163 immunogen Effects 0.000 claims 5
- 101710132601 Capsid protein Proteins 0.000 claims 4
- 101710094648 Coat protein Proteins 0.000 claims 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 101710125418 Major capsid protein Proteins 0.000 claims 4
- 101710141454 Nucleoprotein Proteins 0.000 claims 4
- 101710083689 Probable capsid protein Proteins 0.000 claims 4
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 claims 2
- 150000007824 aliphatic compounds Chemical class 0.000 claims 2
- 150000002894 organic compounds Chemical class 0.000 claims 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical group O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- QJAOYSPHSNGHNC-UHFFFAOYSA-N octadecane-1-thiol Chemical compound CCCCCCCCCCCCCCCCCCS QJAOYSPHSNGHNC-UHFFFAOYSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 본발명에 따르는 복합체의 현미경사진,
제2a도 및 제2b도는 본발명에 따르는 복합체로 면역된 토끼에 있어서 항체반응의 그래프,
제3도는 본발명에 따르는 복합체로 면역된 토끼에 있어서 항체반응의 시간 경과를 나타내는 그래프.
Claims (9)
- 핵구조와 핵구조에 공유결합된 한종류 이상의 다른 합성펩티드의 다수복사체로 구성되며, 핵구조는 사포닌 유도체와 한종류 이상의 활성부분을 갖는 C7내지 C24유기화합물 또는 소수성 펩티드로 구성되고 활성부분은 -COOH, -CHO, -NH2와 -SH의 군으로부터 선택된 것을 특징으로 하는 복합면역원.
- 제 1항에 있어서, 유기화합물은 지방족 화합물인 것을 특징으로 하는 복합면역원.
- 제 2항에 있어서, 지방족화합물은 옥타데칸티올인 것을 특징으로 하는 복합면역원.
- 제 1항에 있어서, 사포닌 유도체는 Quil A.인 것을 특징으로 하는 복합 면역원.
- 제 1항에 있어서, 합성펩티드는 B형 간염비루스 피막단백질의 합성펩티드 유사체인 것을 특징으로 하는 복합면역원.
- 제 1항에 있어서, 상기 합성펩티드는 (1) B형간염 비루스피막단백질의 Pre-S 1영역으로부터 얻은 최소한 한개의 펩티드 유사체, (2) B형간염비루스 피막단백질의 Pre-S 2영역으로부터 얻은 최소한 한개의 펩티드 유사체, 및 (3) B형 간염비루스 피막 단백질의 S영역으로부터 얻은 최소한 한개의 펩티드 유사체로 구성된 것을 특징으로 하는 복합면역원.
- 제 6항에 있어서, 합성 펩티드 유사체(2)는 Pre-S(120∼145)인 것을 특징으로 하는 복합면역원.
- 제 6항에 있어서, 합성펩티드유사체(1)는 Pre-S(21∼47)인 것을 특징으로 하는 복합면역원.
- 제 6항에 있어서 합성펩티드유사체 (3)는 S(135∼155)인 것을 특징으로 하는 복합면역원.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85690986A | 1986-04-28 | 1986-04-28 | |
| US856,909 | 1986-04-28 | ||
| US856909 | 1986-04-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR870010183A true KR870010183A (ko) | 1987-11-30 |
| KR900004313B1 KR900004313B1 (ko) | 1990-06-22 |
Family
ID=25324758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019870004111A KR900004313B1 (ko) | 1986-04-28 | 1987-04-28 | 합성 펩티드를 함유하는 복합 면역원 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0244719B1 (ko) |
| JP (1) | JPS6399018A (ko) |
| KR (1) | KR900004313B1 (ko) |
| CN (1) | CN87103084A (ko) |
| AT (1) | ATE116337T1 (ko) |
| AU (1) | AU7197587A (ko) |
| CA (1) | CA1280972C (ko) |
| DE (1) | DE3750914T2 (ko) |
| DK (1) | DK214087A (ko) |
| ZA (1) | ZA872203B (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0832637B2 (ja) * | 1985-02-14 | 1996-03-29 | アクゾ・エヌ・ヴエー | 合成免疫原 |
| US5039522A (en) * | 1988-01-29 | 1991-08-13 | New York Blood Center, Inc. | Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen |
| US6080725A (en) * | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| AU2003246674B2 (en) * | 2002-07-10 | 2008-08-14 | Intervet International B.V. | Immunogenic composition comprising a fusion protein and a saponin adjuvant |
| CN105154400B (zh) * | 2015-09-30 | 2021-02-02 | 中国人民解放军第三0二医院 | 多克隆抗乙肝病毒免疫细胞的扩增方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4847080A (en) * | 1984-03-07 | 1989-07-11 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers |
| DK17685D0 (da) * | 1985-01-14 | 1985-01-14 | Hans Goeran Magnusson | Glycosidderivater |
-
1987
- 1987-03-25 ZA ZA872203A patent/ZA872203B/xx unknown
- 1987-04-24 AU AU71975/87A patent/AU7197587A/en not_active Abandoned
- 1987-04-25 DE DE3750914T patent/DE3750914T2/de not_active Expired - Fee Related
- 1987-04-25 AT AT87106051T patent/ATE116337T1/de not_active IP Right Cessation
- 1987-04-25 EP EP87106051A patent/EP0244719B1/en not_active Expired - Lifetime
- 1987-04-27 DK DK214087A patent/DK214087A/da not_active Application Discontinuation
- 1987-04-27 JP JP62104175A patent/JPS6399018A/ja active Pending
- 1987-04-27 CN CN198787103084A patent/CN87103084A/zh active Pending
- 1987-04-28 CA CA000535819A patent/CA1280972C/en not_active Expired - Fee Related
- 1987-04-28 KR KR1019870004111A patent/KR900004313B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6399018A (ja) | 1988-04-30 |
| DK214087A (da) | 1987-10-29 |
| ATE116337T1 (de) | 1995-01-15 |
| KR900004313B1 (ko) | 1990-06-22 |
| CA1280972C (en) | 1991-03-05 |
| CN87103084A (zh) | 1988-02-03 |
| EP0244719B1 (en) | 1994-12-28 |
| AU7197587A (en) | 1987-10-29 |
| DE3750914T2 (de) | 1995-05-11 |
| DK214087D0 (da) | 1987-04-27 |
| ZA872203B (en) | 1988-02-24 |
| EP0244719A2 (en) | 1987-11-11 |
| EP0244719A3 (en) | 1990-02-14 |
| DE3750914D1 (de) | 1995-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU90911I2 (fr) | Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare | |
| NO180362C (no) | Fremgangsmåte for fremstilling av cyklosporinholdige preparater | |
| DK103085D0 (da) | Hepatitis-b-peptidimmunogen | |
| DE3865848D1 (de) | Allwetterkarosserieanordnung. | |
| DK200189D0 (da) | Hiv-env-kodet peptid, der kan udvaelge hiv-inhiberende antistoffer hos pattedyr | |
| IT1240314B (it) | Formulazioni acquose stabilizzate di piccoli peptidi. | |
| GB9022190D0 (en) | Immunogenic material | |
| ATE54826T1 (de) | Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung. | |
| EP1375511A3 (en) | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus | |
| NO910209L (no) | Fremgangsmaate for fremstilling av rekombinante humane anti-cd18-antistoffer. | |
| NO870476L (no) | Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater. | |
| MX24890A (es) | Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene. | |
| DE69126577D1 (de) | Antigenes Peptid zum Nachweis von Anti-Hepatitis-C-Virus-Antikörpern und dessen Verwendung | |
| KR870010183A (ko) | 합성 펩티드를 함유하는 복합 면역원 | |
| DE3879968D1 (de) | Malaria-impfstoff aus copolymerem protein. | |
| NO882856D0 (no) | Fremgangsmaate for fremstilling av immunoundertrykkende peptider. | |
| NO891926D0 (no) | Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater. | |
| DE3866747D1 (de) | Jod enthaltende pharmazeutische zubereitung. | |
| ITRM910385A0 (it) | Vaccini utilizzanti eritrociti come veicoli di antigeni. | |
| ATE83930T1 (de) | Antikoerper enthaltende stabilisierte waesserige zusammensetzung. | |
| DE3869939D1 (de) | Biologisch wirksame peptide. | |
| DE494825T1 (de) | Synthetische peptide von hepatitis-b-virus-hbc-antigen. | |
| ATE175357T1 (de) | Empfängnisverhütender impfstoff | |
| DE68915694D1 (de) | Verfahren zur Herstellung von verzweigten 1,3-Glykolen und ihren Monoestern. | |
| TH8954B (th) | สารสำหรับควบคุมความอยากอาหารหรือสารช่วยให้นอนหลับ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 19930522 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |